v3.26.1
Other (Income)/Deductions—Net
 3 Months Ended
Mar. 29, 2026
Other Income and Expenses [Abstract]  
Other (Income)/Deductions—Net Other (Income)/Deductions—Net
Components of Other (income)/deductions––net include:
 Three Months Ended
(MILLIONS)March 29,
2026		March 30,
2025
Interest income$(115)$(143)
Interest expense668 654 
Net interest expense
554 511 
Net (gains)/losses recognized during the period on equity securities
9 370 
Net periodic benefit costs/(credits) other than service costs(72)(158)
Certain legal matters, net(a)
191 142 
Certain asset impairments(b)
— 224 
Changes in fair value of contingent consideration liabilities(c)
295 8 
Other, net
(116)(144)
Other (income)/deductions––net
$861 $953 
(a)The amount for the first quarter of 2026 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2025 included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(b)The amount for the first quarter of 2025 primarily represented an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
(c)See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.